References
[1] Tuohy CV, Kaul S, Song HK, Nazer B, Heitner SB. Hypertrophic
cardiomyopathy: the future of treatment. Eur J Heart Fail
2020;22(2):228-40.
[2] Ozawa K, Funabashi N, Takaoka H, Kobayashi Y. Successful MACE
risk stratification in hypertrophic cardiomyopathy patients using
different 2D speckle-tracking TTE approaches. Int J Cardiol. 2017. 228:
1015-1021.
[3] Lorenzini M, Anastasiou Z, O’Mahony C, et al. Mortality Among
Referral Patients With Hypertrophic Cardiomyopathy vs the General
European Population. JAMA Cardiol. 2020. 5(1): 73-80.
[5] Flenner F, Jungen C, Küpker N, et al. Translational
investigation of electrophysiology in hypertrophic cardiomyopathy. J Mol
Cell Cardiol. 2021. 157: 77-89.
[6] Huurman R, Schinkel A, van der Velde N, et al. Effect of body
surface area and gender on wall thickness thresholds in hypertrophic
cardiomyopathy. Neth Heart J. 2020. 28(1): 37-43.
[7] McLELLAN AJ, Ellims AH, Prabhu S, et al. Diffuse Ventricular
Fibrosis on Cardiac Magnetic Resonance Imaging Associates With
Ventricular Tachycardia in Patients With Hypertrophic Cardiomyopathy. J
Cardiovasc Electrophysiol. 2016. 27(5): 571-80.
[8] Smith ED, Tome J, Mcgrath R, et al. Exercise hemodynamics in
hypertrophic cardiomyopathy identify risk of incident heart failure but
not ventricular arrhythmias or sudden cardiac death. Int J Cardiol.
2019. 274: 226-231.
[9] Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ.
Magnitude of left ventricular hypertrophy and risk of sudden death in
hypertrophic cardiomyopathy. N Engl J Med 2000;342(24):1778-85.
[10] Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC
Guidelines on diagnosis and management of hypertrophic cardiomyopathy:
the Task Force for the Diagnosis and Management of Hypertrophic
Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J.
2014. 35(39): 2733-79.
[11] Musumeci B, Tini G, Russo D, et al. Left Ventricular Remodeling
in Hypertrophic Cardiomyopathy: An Overview of Current Knowledge. J Clin
Med. 2021. 10(8).
[12] Losi MA, Imbriaco M, Canciello G, Pacelli F, Di Nardo C,
Lombardi R, et al. Left ventricular mass in hypertrophic cardiomyopathy
assessed by 2d-echocardiography: validation with magnetic resonance
imaging. J Cardiovasc Transl Res 2020;13(2):238-44.
[13] Losi MA, Imbriaco M, Canciello G, et al. Left Ventricular Mass
in Hypertrophic Cardiomyopathy Assessed by 2D-Echocardiography:
Validation with Magnetic Resonance Imaging. J Cardiovasc Transl Res.
2020. 13(2): 238-244.
[14] Sreedharan S, Mathew A, Paul Z, et al. Changes in Left
Ventricular Mass and Cardiovascular Risk Factors after Kidney
Transplantation. Saudi J Kidney Dis Transpl. 2020. 31(5): 1006-1013.
[15]Beydoun MA, Shaked D, Hossain S, et al. Red cell distribution
width, anemia and their associations with white matter integrity among
middle-aged urban adults. Neurobiol Aging. 2021. 105: 229-240.
[16] Tonelli M, Sacks F, Arnold M, Moye L, Davis B, Pfeffer M, et
al. Relation between red blood cell distribution width and
cardiovascular event rate in people with coronary disease. Circulation
2008;117(2):163-8.
[17] Ulrich A, Wharton J, Thayer TE, Swietlik EM, Assad TR, Desai
AA, et al. Mendelian randomisation analysis of red cell distribution
width in pulmonary arterial hypertension. Eur Respir J
2020;55(2):1901486.
[18] Xanthopoulos A, Papamichalis M, Zajichek A, Milinovich A,
Kattan MW, Skoularigis J, et al. In-hospital red blood cell distribution
width change in patients with heart failure. Eur J Heart Fail
2019;21(12):1659-61.
[19] Yang HJ, Liu X, Qu C, Shi SB, Liang JJ, Yang B. Usefulness of
red blood cell distribution width to predict heart failure
hospitalization in patients with hypertrophic cardiomyopathy. Int Heart
J 2018;59(4):779-85.
[20] Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs
I, et al. Echocardiographic assessment of left ventricular hypertrophy:
comparison to necropsy findings. Am J Cardiol 1986;57(6):450-8.
[21] Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E,
Pellikka PA, et al. Recommendations for chamber quantification. Eur J
Echocardiogr 2006;7(2):79-108.
[22] Nakatani S, Marwick TH, Lever HM, Thomas JD. Resting
echocardiographic features of latent left ventricular outflow
obstruction in hypertrophic cardiomyopathy. Am J Cardiol
1996;78(6):662-7.
[23] DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas
under two or more correlated receiver operating characteristic curves: a
nonparametric approach. Biometrics 1988;44(3):837-45.
[24] Zhu L, Wang J, Wang Y, Jia L, Sun K, Wang H, et al. Plasma uric
acid as a prognostic marker in patients with hypertrophic
cardiomyopathy. Can J Cardiol 2015;31(10):1252-8.
[25] Meng XB, Wang WY, Zhang K, Qi Y, An SM, Wang SY, et al. Value
of N-terminal pro-B-type natriuretic peptide on long-term outcome of
patients with hypertrophic cardiomyopathy. Zhonghua Xin Xue Guan Bing Za
Zhi 2018;46(3):192-7. (in Chinese)
[26] Hasler S, Manka R, Greutmann M, Gämperli O, Schmied C, Tanner
FC, et al. Elevated high-sensitivity troponin T levels are associated
with adverse cardiac remodelling and myocardial fibrosis in hypertrophic
cardiomyopathy. Swiss Med Wkly 2016;146:w14285.
[27] Stanzani G, Cowlam R, English K, Connolly DJ. Evaluation of red
blood cell distribution width in cats with hypertrophic cardiomyopathy.
J Vet Cardiol 2015;17:S233-43.
[28] Viswanath D, Hegde R, Murthy V, Nagashree S, Shah R. Red cell
distribution width in the diagnosis of iron deficiency anemia. Indian J
Pediatr 2001;68(12):1117-9.
[29] D’Alessandro A, Blasi B, D’Amici GM, Marrocco C, Zolla L. Red
blood cell subpopulations in freshly drawn blood: application of
proteomics and metabolomics to a decades-long biological issue. Blood
Transfus 2013;11(1):75-87.
[30] Tsimikas S, Willerson JT, Ridker PM. C-reactive protein and
other emerging blood biomarkers to optimize risk stratification of
vulnerable patients. J Am Coll Cardiol 2006;47:C19-31.
[31] Okonko DO, Marley SB, Anker SD, Poole-Wilson PA, Gordon MY.
Suppression of erythropoiesis in patients with chronic heart failure and
anaemia of unknown origin: evidence of an immune basis. Int J Cardiol
2013;166(3):664-71.
[32] Chen L, Li Z, Li Y, Xue J, Chen P, Yan S, et al. Red cell
distribution width and inappropriateness of left ventricular mass in
patients with untreated essential hypertension. PLoS One
2015;10(3):e0120300.
[33] Gromadziński L, Januszko-Giergielewicz B, Pruszczyk P. Red cell
distribution width is an independent factor for left ventricular
diastolic dysfunction in patients with chronic kidney disease. Clin Exp
Nephrol 2015;19(4):616-25.
[34] Yao HM, Wang XL, Peng X, Chen SY, Wan X, Zuo W, et al.
Increased red blood cell distribution width might predict left
ventricular hypertrophy in patients with atrial fibrillation. Medicine
(Baltimore). 2020;99(37):e22119.
[35] Tse G, Yan BP, Chan YW, Tian XY, Huang Y. Reactive oxygen
species, endoplasmic reticulum stress and mitochondrial dysfunction: the
link with cardiac arrhythmogenesis. Front Physiol 2016;7:313.